EOS imaging (Euronext, FR0011191766 - EOSI - Eligible for PEA: French
SME Share Savings Schemes) (Paris:EOSI), the pioneer in 2D/3D medical
orthopedic imaging, today announced its consolidated half-year revenues
for the period ended June 30, 2014.
The Company sold 15 EOS® systems during the first half, compared to 11
during the same period last year. With a stable average selling price of
€391,000, revenues from sales of equipment totaled €5.86 million, an
increase of 36%.
Sales of services, which were driven by the increase in installed
equipment under contracts, rose by 55% to €0.93 million compared with
€0.60 million last year.
Sales of consumables and related services by the Company's OneFit
Medical subsidiary amounted to €0.32 million in the first half of 2014.
EOS recorded excellent sales momentum in Asia during the first half of
2014, which included the sale of seven systems, generating revenues of
The performance in Asia offset the impact of the downturn recorded in
the North American market, where sales decreased by 55% to €1.18 million
in the first half of 2014, compared with €2.63 million at the end of
EOS continued to register robust growth in the EMEA Region (+41%), where
it generated revenues of €3.22 million as compared to €2.28 million last
Figures subject to limited review
EOS imaging sold 11 EOS® systems in the second quarter of 2014 and
generated revenues of €4.96 million, an increase of 65% as compared to
the second quarter of 2013.
Marie Meynadier, CEO of EOS imaging, made the following comments: "Our
positive half-year performance reflects the ongoing adoption of our
technology in new markets. Our excellent momentum in the Asian and
European markets enabled us to register strong growth during the
half-year despite a challenging environment for capital equipment in the
North American market. We are pursuing our marketing strategy in order
to ensure the increased adoption of EOS in the three major markets where
we currently operate."
For more information, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and
patented medical imaging system, based on technology that enabled George
Charpak to win the Nobel Prize for Physics. The Company is authorized to
market the system in 31 countries, including the United States (FDA),
Japan, Canada, Australia and the European Union (EU). Backed by an
installed base of 90 sites and more than 400,000 imaging sessions, EOS®
benefits from worldwide recognition within the global medical community.
As of December 31, 2013 the Group posted 2013 consolidated revenue of
€15.2 million and employed 101 people including an R&D team of 38
engineers. The Group is based in Paris and holds four subsidiaries in
Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and
Frankfurt (Germany), and offices in Singapore. For further information,
please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 - Ticker: EOSI
Next press release: 2014 first half results, on Sept. 1, 2014 (after
[ Back To NFVZone's Homepage ]